$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come
It was Axel Bolte’s work as a venture partner for HBM that originally took him to the campus at Yale, with a chance to start meeting the scientists there. And that introduction eventually led him to Demetrios Braddock, who had been doing lab work on calcification that he’s devoutly hoping could have an impact on a long line of diseases.
“Ultimately I always wanted to be directly involved as an entrepreneur and operational in companies,” says Bolte, “which is what I did before in large organizations.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.